OR WAIT null SECS
A research team led by scientists at AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU) invents a universal antibody drug against HIV/AIDS. By engineering a tandem bi-specific broadly neutralizing antibody, the team found that this novel antibody drug is universally effective not only against all genetically divergent global HIV-1 strains tested but also promoting the elimination of latently infected cells in a humanized mouse model. The new findings are now published in the April issue of Journal of Clinical Investigation.
AIDS remains an incurable disease. In the world, HIV/AIDS has resulted in estimated 40 million deaths while 36.9 million people are still living with the virus. To end the HIV/AIDS pandemic, it is important to discover either an effective vaccine or a therapeutic cure. There are, however, two major scientific challenges: the tremendous HIV-1 diversity and the antiviral drug-unreachable latency. Since it is extremely difficult to develop an appropriate immunogen to elicit broadly neutralizing antibodies (bnAbs) against genetically divergent HIV-1 subtypes, developing existing bnAbs as passive immunization becomes a useful approach for HIV-1 prophylaxis and immunotherapy.
Previous studies have investigated the potency, breadth and crystal structure of many bnAbs including their combination both in vitro and in vivo. Naturally occurring HIV-1 resistant strains, however, are readily found against these so-called bnAbs and result in the failure of durable viral suppression in bnAb-based monotherapy. To improve HIV-1 neutralization breadth and potency, bispecific bnAb, which blocks two essential steps of HIV-1 entry into target cells, have been engineered and show promising efficacy in animal models. Before the publication, tandem bi-specific bnAb has not been previously investigated in vivo against HIV-1 infection.
The HKU research team invented a single gene-encoded tandem broadly neutralizing antibody, titled BiIA-SG. By attaching to host protein CD4, BiIA-SG strategically ambushes invading HIV-1 particles to protect CD4 positive T cells. BiIA-SG not only displays a potent activity against all three panels of 124 genetically divergent global HIV-1 strains tested, but also prevents diverse live viral challenges completely in humanized mice. Moreover, gene transfer of BiIA-SG achieves pro-longed drug availability in vivo, leading to a promising efficacy of eliminating HIV-1 infected cells in humanized mice. Therefore, the research team provides a proof-of-concept that BiIA-SG is a novel universal antibody drug for prevention and immunotherapy against HIV-1 infection.
The accumulated number of HIV-1 infections has more than doubled from 4,443 diagnostic cases in 2009 to 9,091 in 2017, despite the timely introduced combination antiretroviral therapy and prevention interventions in Hong Kong. Currently, the estimated annual cost is over HK$550 millions for antiretroviral drugs alone per year in Hong Kong, not to mention the rising issues of life-long financial burdens, drug toxicity and resistant viruses. The newly invented universal antibody drug brings the hope to fight these issues. With significantly improved breadth and potency, BiIA-SG will hopefully be the first "Made in Hong Kong" anti-HIV-1 antibody drug for clinical development.
The research was primarily conducted by the HKU team led by professor Chen Zhiwei, director of the AIDS Institute and professor in the Department of Microbiology. Four graduate students Xilin Wu, Jia Guo, Mengyue Niu, Ka Shing Lam and Research assistant professor Dr Li Liu of Department of Microbiology made major contributions. Key external collaborators include Dr. Hui Wang at Shenzhen Third People's Hospital, professor Hong Shang at The First Affiliated Hospital of China Medical University, professor Xia Jin and professor Paul Zhou at Institut Pasteur of Shanghai of Chinese Academy of Sciences, and professor Linqi Zhang at Tsinghua University.
The work was supported by the Hong Kong RGC/NSFC (N_HKU709/11), HMRF(12110952), RGC(HKU5/CRF/13G), ITF(ITS/170/17), China's National Science and Technology Major Project (2013ZX10001005002001), National Natural Science Foundation Award (81530065), Grand Challenge China (81661128042), the Sanming Project of Medicine in Shenzhen, HKU University Development Fund and The Li Ka Shing Faculty of Medicine Matching Fund to the HKU AIDS Institute, for financial supports.
Source: University of Hong Kong